OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: targeted drug combo enters phase 2 trial
Disease control OngoingThis phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug cocktail shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find …
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Measles virus hijacks stem cells to attack ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC